Viken, August 20th, 2018 — TIKOMED, a specialty pharmaceutical company focused on developing therapeutics for treating acute and degenerative neurological and ophthalmic diseases, has been granted permission by the UK Medicines and Healthcare products Regulatory Agency, for a phase II clinical trial of the company’s investigational drug ILB for patients with Amyotrophic Lateral Sclerosis (ALS), to be conducted at Birmingham University Hospital.
Anders Svenson M.D., Chief Medical Officer of TIKOMED, commented, “We are very pleased that the UK Medicines and Healthcare products Regulatory Agency has granted us permission for our phase II clinical trial for patients with ALS. With this decision, we continue to deliver on our clinical roadmap and we strongly believe that this clinical trial, to be conducted at Birmingham University Hospital, will demonstrate the safety and tolerability of ILB in the treatment of ALS.”
With Dr. Venkataramanan Srinivasan as principal investigator, the clinical trial will be conducted at and in collaboration with Birmingham University Hospital, Birmingham, United Kingdom. 15 patients with ALS will receive ILB for a 10-week treatment period, in the trial, which will be initiated within the coming months.
Anders Kristensson, Chief Executive Officer of TIKOMED, commented, “ALS is a debilitating disease with no cure and as current treatment options focus on slowing the progression of the disease, we are excited about ILB’s unique mechanism of action of triggering self-repair and protection. We are hopeful that this might present new possibilities for both patients and caregivers impacted by this terrible disease.”
Tikomed will also be running a phase II ALS study in collaboration with Sahlgrenska University Hospital in Sweden. In this trial, 15 patients with ALS will receive ILB for a 4-week treatment period.